Key result
MRAs cut incident CTRCD ~94% in cancer patients, leading cardioprotective regimens.
Why the study?
Clinical trials evaluating cardioprotective strategies for anthracycline and anti-HER2 therapy are heterogeneous and lack direct comparisons between drug classes, leaving the optimal pharmacologic approach to primary prevention of cancer therapy-related cardiac dysfunction uncertain.
Do pharmacologic cardioprotective therapies (beta-blockers, ACE inhibitors, ARBs, MRAs, statins, ARNIs, and combination regimens) prevent clinically meaningful cancer therapy-related cardiac dysfunction (LVEF <50%) in adults receiving anthracycline- and/or anti-HER2-based chemotherapy?
Meta-Analysis
Randomised controlled trials included
Do pharmacologic cardioprotective therapies (beta-blockers, ACE inhibitors, ARBs, MRAs, statins, ARNIs, and combination regimens) prevent clinically meaningful cancer therapy-related cardiac dysfunction (LVEF <50%) in adults receiving anthracycline- and/or anti-HER2-based chemotherapy?
In cancer patients receiving anthracycline or anti-HER2 therapy, MRAs, dual neurohormonal therapy, ACE inhibitors, beta-blockers, and statins significantly reduce the risk of LVEF dropping below 50%, whereas ARBs show no consistent efficacy.
MRAs merit consideration for CTRCD prevention in anthracycline/anti-HER2 recipients; extends network meta-analysis ranking of 42 RCTs.
Background Cancer therapy-related cardiac dysfunction (CTRCD) is an important complication of cancer treatment that may lead to interruption of treatment. Anthracyclines and anti-HER2 therapies are highly effective but carry risk of myocardial injury, ranging from subclinical changes to overt heart failure. Clinical trials data evaluating cardioprotective strategies remain heterogeneous and lacking direct comparisons between drug classes. Consequently, the optimal pharmacologic approach to cardioprotection remains uncertain. We performed a systematic review and network meta-analysis (NMA) of randomised trials evaluating pharmacologic strategies for primary prevention of CTRCD. Methods MEDLINE and Embase were searched from inception to Feb 2026. We included randomised controlled trials enrolling adults receiving anthracycline- and/or anti-HER2–based chemotherapy that evaluated primary prevention of CTRCD. Interventions included beta-blockers, ACE inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRA), statins, angiotensin receptor–neprilysin inhibitors (ARNI), and combination regimens. The primary outcome was incidence of clinically meaningful CTRCD (LVEF <50%). Secondary outcomes were study-defined cardiotoxicity (which have changed in definition over time) and absolute change in LVEF. Where LVEF <50% was not reported, proportions were derived assuming normal distribution of follow-up LVEF values. Results Forty-two trials (94 treatment arms) were included. For incident LVEF <50%, MRAs demonstrated the largest effect (OR 0.06, 95% CI 0.01–0.44), followed by dual therapy [beta blocker + ACEi/ARB] (OR 0.26, 0.10–0.66) and ACE inhibitors (OR 0.29, 0.10–0.85). Beta-blockers (OR 0.55, 0.33–0.91) and statins (OR 0.52, 0.29–0.94) were also associated with reduced risk, while ARBs and ARNIs were not significant.Secondary analyses suggested divergence across endpoints. Using contemporary, study-defined cardiotoxicity criteria, statins and ARNIs performed best, whereas ACE inhibitors did not demonstrate consistent benefit. ARBs showed no signal of efficacy across outcomes. Conclusions Cardioprotective therapy was associated with reduced CTRCD, with effects varying by drug class and outcome definition. Therapies traditionally targeting neurohormonal pathways were most consistently associated with preservation of LVEF, whereas statins and ARNIs showed greater benefit when broader, study-defined cardiotoxicity criteria were applied. In contrast, ARBs demonstrated no consistent signal of efficacy across analyses. Treatment benefit is sensitive to outcome definition, which may partly explain heterogeneity across trials. These findings may have important clinical implications for the choice of cardioprotective therapies in cancer patients undergoing anthracycline or anti-HER2 based therapy.Table 1Figure 1
No takes yet. Share an insight, caveat, or question.
Maharajan et al. (2026) conducted a meta-analysis in Cancer therapy-related cardiac dysfunction (CTRCD) in patients receiving anthracycline- and/or anti-HER2-based chemotherapy. Cardioprotective pharmacologic strategies (MRAs, beta-blockers, ACE inhibitors, ARBs, statins, ARNIs, and combination regimens) vs. Control or alternative cardioprotective drug classes was evaluated on Incidence of clinically meaningful CTRCD (LVEF <50%) (OR 0.06, 95% CI 0.01-0.44). MRAs (OR 0.06, 95% CI 0.01–0.44), beta-blocker + ACEi/ARB dual therapy (OR 0.26), ACEis (OR 0.29), statins (OR 0.52), and beta-blockers (OR 0.55) reduced incident LVEF <50% in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: